Elsevier

Biochemical Pharmacology

Volume 39, Issue 7, 1 April 1990, Pages 1187-1192
Biochemical Pharmacology

Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)-urea

https://doi.org/10.1016/0006-2952(90)90261-IGet rights and content

Abstract

The cellular pharmacology of N-(4-methylphenylsulfonyl)-N-(4-chlorophenyl)-urea (MPCU) has been examined in a cloned line of GC3 human colon adenocarcinoma cells. There was a rapid concentrative accumulation of drug, which could be separated into energy-independent and -dependent phases. Accumulation over 15 sec was linear and temperature dependent, but not energy dependent (azide insensitive). The rate of uptake was a linear function of concentration over a wide range (0.0026 to 5 mM). No saturation kinetics were demonstrated. Steady state was achieved within 10 min, and drug levels associated with GC3c1 cells exceeded the extracellular concentration by 4- to 6-fold. This second phase “concentrative accumulation” of drug was azide sensitive. When cells were incubated to steady state in the presence of azide, removal of azide (with addition of glucose) resulted in a further uptake of sulfonylurea to a higher steady state. When [3H]MPCU was removed from the medium after achieving steady state, loss of drug from cells was rapid (T12≈ 130sec), and no tightbinding component was apparent. After achieving steady state, cell-associated drug was lost into drugcontaining medium reaching a lower steady state if 10 mM azide (± glucose) was added. These data indicate that MPCU may enter cells by a non-saturable energy-independent process (passive diffusion) and bind weakly to some intracellular component or become sequestered to some compartment in an energy-dependent manner.

References (17)

There are more references available in the full text version of this article.

Cited by (39)

  • 2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers

    2011, Bioorganic and Medicinal Chemistry
    Citation Excerpt :

    Sulfonylurea derivatives represent another important class of biologically active compounds with a broad spectrum of activity in several solid tumour models.23 A compound from this class, sulofenur (LY186641, 3) has been clinically evaluated in many cancer cell lines.24–26 These compounds are known to exert their biological effect by inhibiting DNA, RNA, or protein synthesis.27,28

  • Synthesis and antitumor evaluation of novel diarylsulfonylurea derivatives: Molecular modeling applications

    2010, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Diarylsulfonylureas have been identified as a new class of cancer chemotherapeutic agents with significant therapeutic efficacy against solid tumors [1–13]. Among these compounds, remarkable effectiveness of LY186641 (A, Sulofenur) and LY295501 (B) has been demonstrated against advanced colon adenocarcinoma xenografts intrinsically resistant to virtually all standard chemotherapeutic agents and had very significant activity against several pediatric tumors grown as xenografts (Scheme 1) [5,8,9,14–18]. Even though the mechanism of actions of these compounds has not been elucidated, it is estimated that diarylsulfonylureas act on mitochondria and are different from other clinically used antineoplastic agents in view of potency and toxicity [15,16].

  • Induction of G<inf>2</inf>/M phase arrest and apoptosis by a new synthetic anti-cancer agent, DW2282, in promyelocytic leukemia (HL-60) cells

    2001, Biochemical Pharmacology
    Citation Excerpt :

    Diarylsulfonylureas are membrane-active and weak uncouplers of mitochondrial oxidative phosphorylation. Thus, the mitochondria have been suggested as a possible site of action [24–26]. However, it has also been reported that the anti-cancer activity of diarylsulfonylureas is not the result of their uncoupling action [26].

View all citing articles on Scopus
View full text